# Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

> **NCT02791230** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1733 (actual)

## Conditions studied

- Transthyretin (TTR) Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Tafamidis

## Key facts

- **NCT ID:** NCT02791230
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-11-02
- **Target enrollment:** 1733 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791230, "Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02791230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*